CD274 and neoplasm: Furthermore, we incorporate immune checkpoint inhibitors (ICIs), anti-human PD-1 (pembrolizumab), or anti-human PD-L1 (atezolizumab) antibodies to GD2-EAT or HER2-EAT therapy and study the optimal inhibitor and combination schedule in order to improve their anti-tumor response.